

21 January 2026

ASX Announcement

Nasodine Throat Spray Product Launch in Singapore

- **Nasodine® Throat Spray, now launched in its first international market – Singapore. Plans for its launch in other international markets in 2026**
- **Throat spray is an important complementary product to Nasodine® Nasal Spray**
- **More innovative Nasodine products to follow in 2026**

Firebrick Pharma Limited (ASX:FRE) (Company or Firebrick) is very pleased to announce that its first new product – Nasodine® Throat Spray – has been launched in Singapore. This follows successful completion of commercial manufacturing in Australia in November and December 2025, and shipment to Singapore in early January 2026 (refer previous ASX announcement dated 30 October 2025).

Nasodine Throat Spray is a 1% povidone-iodine solution designed for oral use. The Company considers the new throat spray to be a valuable complement to Nasodine Nasal Spray because it targets sore throats, which are often the first sign of the common cold.

“Nasodine Throat Spray provides a compact, easy-to-use and pleasant tasting solution for sore throats,” said Firebrick Executive Chairman, Dr Peter Molloy. “In conjunction with our nasal spray, the new throat spray gives cold sufferers a comprehensive nasal and oral solution for protection and relief of colds. We believe the convenience of the throat spray compared to oral gargles is a major benefit; it’s perfect for travel, commuting and other on-the-go uses.”

Nasodine Throat Spray is being launched in Singapore by the Company’s exclusive licensing partner, Innorini Life Sciences (“Innorini”). For the first six months Innorini’s focus will be on hospitals and healthcare professionals (“HCPs”), after which the new throat spray will be made available to the retail channel.

Innorini Managing Director, Rishi Nandiraju stated:

“Following the strong response to Nasodine Nasal Spray in Singapore, we are extremely excited to introduce the Nasodine Throat Spray to the market. This represents a natural extension of the brand and a significant opportunity to strengthen Nasodine as a comprehensive first-line antiseptic solution for upper respiratory care. We see strong potential across both the HCP and retail channels, and we look forward to working closely with Firebrick to build Nasodine into a trusted household name in Singapore.”

Firebrick also expects to see the Nasodine Throat Spray introduced in Fiji and USA during 2026, and in other markets in the future where Nasodine Nasal Spray is approved. Other new Nasodine products are also planned for introduction in existing markets in 2026.

“We are aiming to build a valuable Nasodine franchise that based multiple products across multiple markets,” added Dr Molloy.

About Nasodine Throat Spray



Nasodine Product Range now Available in Singapore
(Nasodine products are not available in Australia)

Nasodine® Throat Spray is a 1% povidone-iodine sore throat treatment in a formulation designed for oral use. This compares with Nasodine Nasal Spray, which is 0.5% povidone-iodine in a formulation specifically designed for safe nasal use. Both products use the same custom-designed 25mL bottle but with different spray pumps.

The new throat spray features a compact, convenient and ready-to-use design, combined with a pleasant tasting formulation. The incorporated nozzle provides precise targeting of solution directly to the affected area. The low volume per spray (around 0.2 mL) means there is no need to expectorate (spit out) unused solution, avoiding the potential staining and inconvenience of the gargle format.

The product is not approved for sale in Australia. In Singapore unlike Australia, Nasodine Throat Spray and Nasodine Nasal Spray can be sold as antiseptics and do not require local regulatory approval prior to marketing. However, the Company has received a permit from the Therapeutic Goods Administration (<https://www.tga.gov.au/resources/artg/517465>), allowing export of Nasodine Throat Spray product from Australia. The product is now available for purchase online in Singapore through nasodine-sg.com. To meet the local market pricing of similar products, Nasodine Throat Spray is priced at S\$19.99 each, which is 20% lower than Nasodine Nasal Spray at S\$24.99 (before volume and other discounts).

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Ltd.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed and manufactured Nasodine® Nasal Spray (0.5% PVP-I), which so far has been introduced into the United States, Singapore and Fiji & South Pacific. The Company is pursuing approval in other markets, including the Philippines. Nasodine® Throat Spray is the first follow-on product, now available in Singapore. For further information, visit <https://nasodine-sg.com/>